225
Views
19
CrossRef citations to date
0
Altmetric
REVIEW ARTICLE

MASPIN tumour-suppressing activity in head and neck squamous cell carcinoma: Emerging evidence and therapeutic perspectives

, , , &
Pages 476-480 | Received 02 May 2008, Published online: 08 Jul 2009

References

  • Beltran A, Parikh S, Liu Y, Cuevas BD, Johnson GL, Futscher BW, et al. Re-activation of a dormant tumor suppressor gene maspin by designed transcription factors. Oncogene 2007; 26: 2791–8
  • Bailey CM, Khalkhali-Ellis Z, Seftor EA, Hendrix MJ. Biological functions of maspin. J Cell Physiol 2006; 209: 617–24
  • Yu M, Zheng H, Tsuneyama K, Takahashi H, Nomoto K, Xu H, et al. Paradoxical expression of maspin in gastric carcinomas: correlation with carcinogenesis and progression. Hum Pathol 2007; 38: 1248–55
  • Marioni G, Giacomelli L, D'Alessandro E, Marchese-Ragona R, Staffieri C, Ferraro SM, et al. Nuclear localization of maspin: is its impact on the prognosis in laryngeal carcinoma due to a pro-apoptotic effect?. Am J Otolaryngol 2008; 29: 156–62
  • Khalkhali-Ellis Z. Maspin: the new frontier. Clin Cancer Res 2006; 12: 7279–83
  • Ho T, Wei Q, Sturgis EM. Epidemiology of carcinogen metabolism genes and risk of squamous cell carcinoma of the head and neck. Head Neck 2007; 29: 682–99
  • Marioni G, Blandamura S, Giacomelli L, Calgaro N, Segato P, Leo G, et al. Nuclear expression of maspin is associated with a lower recurrence rate and a longer disease free interval after surgery for squamous cell carcinoma of the larynx. Histopathology 2005; 46: 576–82
  • Lonardo F, Li X, Siddiq F, Singh R, Al-Abbadi M, Pass Hi, et al. Maspin nuclear localization is linked to favorable morphological features in pulmonary adenocarcinoma. Lung Cancer 2006; 51: 31–9
  • Sood AK, Fletcher MS, Gruman LM, Coffin JE, Jabbari S, Khalkhali-Ellis Z, et al. The paradoxical expression of maspin in ovarian carcinoma. Clin Cancer Res 2002; 8: 2924–32
  • Solomon LA, Munkarah AR, Schimp VL, Arabi MH, Morris RT, Massar H, et al. Maspin expression and localization impact on angiogenesis and prognosiss in ovarian cancer. Gynecol Oncol 2006; 1001: 385–9
  • Xia W, Lau YK, Hu MC, Li L, Johnston DA, Sheng S, et al. High tumoral maspin expression is associated with improved survival of patients with oral squamous cell carcinoma. Oncogene 2000; 19: 2398–403
  • Yasumatsu R, Nakashima T, Hirakawa N, Kumamoto Y, Kuratomi Y, Tomita K, et al. Maspin expression in stage I and II oral tongue squamous cell carcinoma. Head Neck 2001; 23: 962–6
  • Cho JH, Kim HS, Park CS, Kim JK, Jung KY, Shin BK, et al. Maspin expression in early oral tongue cancer and its relation to expression of mutant-type p53 and vascular endothelial growth factor (VEGF). Oral Oncol 2007; 43: 272–7
  • Iezzi G, Piattelli A, Rubini C, Goteri G, Artese L, Perrotti V, et al. Maspin expression in oral squamous cell carcinoma. J Craniofac Surg 2007; 18: 1039–43
  • Marioni, G, Gaio, E, Giacomelli, L, Bertolin, A, D'Alessandro, E, Stramare, R, , et al. Maspin subcellular localization and expression in oral cavity squamous cell carcinoma Eur Arch Otorhinolaryngol 2008; 265(Suppl 1):s97–s104.
  • Marioni G, D'Alessandro E, Giacomelli L, De Filippis C, Calgaro N, Sari M, et al. Maspin nuclear localization is related to reduced density of tumour-associated microvessels in laryngeal carcinoma. Anticancer Res 2006; 26: 4927–32
  • Marioni G, Ottaviano G, Giacomelli L, Staffieri C, Casarotti-Todeschini S, Bonandini E, et al. CD105-assessed micro-vessel density is associated with malignancy recurrence in laryngeal squamous cell carcinoma. Eur J Surg Oncol 2006; 32: 1149–53
  • Koornstra JJ, Rijcken FE, De Jong S, Hollema H, de Vries EG, Kleibeuker JH. Assessment of apoptosis by M30 immunoreactivity and the correlation with morphological criteria in normal colorectal mucosa, adenomas and carcinomas. Histopathology 2004; 44: 9–17
  • Mhawech-Fauceglia P, Dulguerov P, Beck A, Bonet M, Allal AS. Value of ezrin, maspin and nm23-H1 protein expressions in predicting outcome of patients with head and neck squamous-cell carcinoma treated with radiotherapy. J Clin Pathol 2007; 60: 185–9
  • Beltran AS, Sun X, Lizardi PM, Blancafort P. Reprogramming epigenetic silencing: artificial transcription factors synergize with chromatin remodelling drugs to reactivate the tumor suppressor mammary serine protease inhibitor. Mol Cancer Ther 2008; 7: 1080–90
  • Russo, A, Terrasi, M, Agnese, V, Santini, D, Bazan, V. Apoptosis: a relevant toll for anticancer therapy Ann Oncol 2006;17((Suppl 7)):vii115–vii123.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.